Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study

BMC Nephrology

Guido Filler²  Joaquín Madrenas³  Luan Chau¹  Daisy Liu⁴  Abeer Yasin⁴ 

[1] Department of Microbiology and Immunology, and Medicine, and Center for Human Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, N6A 3K7, Canada;Department of Pathology and Laboratory Medicine, DSB 4044, Schulich School of Medicine and Dentistry, University f Western Ontario, London, Ontario, N6A 3K7, Canada;Department of Microbiology & Immunology, McGill University, Room 511, Duff Medical Building, Montreal, Quebec, H3A 2B4, Canada;Department of Pediatrics, Children’s Hospital, London Health Science Center, University of Western Ontario, 800 Commissioners Road East, London, Ontario, N6A 5W9, Canada

关键词: Calcium phosphate product;    Renal osteodystrophy;    Parathyroid hormone;    Fibroblast growth factor 23;    Chronic kidney disease;   

Others  :  1082999
DOI  :  10.1186/1471-2369-14-39

 received in 2012-02-29, accepted in 2013-02-13,  发布年份 2013

【 摘 要 】

Background

Fibroblast growth factor-23 (FGF-23), a novel marker of bone disease in chronic kidney disease (CKD) has been shown to correlate with vascular calcifications. We aimed to describe the effect of the calcium phosphate product (Ca*P) on FGF-23 concentrations in children and young adults without confounding cardiovascular disease.

Methods

Pediatric and young adult patients with CKD stages I-V were recruited in this cross sectional study to measure FGF-23, cystatin C, vitamin D-metabolites and other serum markers of bone metabolism. FGF-23 levels were determined with an enzyme-linked immunosorbent assay. The association between FGF-23 and (Ca*P) was assessed using non-parametric methods. Patients were divided into two age groups, less than 13 years of age and greater than 13 years of age.

Results

This cross-sectional study measured serum FGF-23, in 81 patients (42 females, 51.9%) at London Health Sciences Centre, aged 2 to 25 years, with various stages of CKD (Cystatin C estimated glomerular filtration rate, eGFR=10.7-213.0 ml/min). For the whole entire group of patients, FGF-23 levels were found to correlate significantly with age (Spearman r= 0.26, p=0.0198), Cystatin C eGFR (Spearman r=−0.40 p=0.0002), CKD stage (Spearman r=0.457, p<0.0001), PTH (Spearman r=0.330, p=0.0039), ionized calcium (Spearman r=−0.330, p=0.0049), CysC (Spearman r= 0.404, p=0.0002) and 1,25-dihydroxyvitamin D (Spearman r=−0.345, p=0.0034) concentrations. No significant correlation was found between FGF-23 levels and calcium phosphate product (Spearman r= 0.164, p=0.142). Upon classification of patients into two age groups, less than 13 years of age and more than 13 years of age, correlational results differed significantly. FGF-23 correlated with CysC eGFR( Spearman r= −0.633, p<0.0001), CKD stage (Spearman r=0.731, p<0.0001), phosphate (Spearman r= 0.557, p<0.0001), calcium phosphate product (Spearman r=0.534, p<0.0001), 125(OH)2 Vit D (Spearman r=−0.631, p<0.0001), PTH (Spearman r= 0.475, p=0.0017) and ionized calcium (Spearman r= −0.503, p=0.0015) only in the older group. The relationship between FGF-23 and Ca*P for the older group could be expressed by the exponential model FGF-23= 38.15 e^0.4625Ca*P.

Conclusion

Abnormal values of FGF-23 in adolescents and young adults with CKD correlate with Ca* P in the absence of vascular calcifications, and may serve as a biomarker for the risk of cardiovascular calcifications.

【 授权许可】

   
2013 Yasin et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Westerberg PA, Linde T, Wikstrom B, Ljunggren O, Stridsberg M, Larsson TE: Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 2007, 22:3202-3207.
• [2]Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y: Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010, 5:1268-1276.
• [3]Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K: Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009, 45:1161-1168.
• [4]Holden RM, Beseau D, Booth SL, Adams MA, Garland JS, Morton RA, Collier CP, Foley RN: FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. Hemodial Int 2011. in press
• [5]Goodman WG: Vascular calcification in chronic renal failure. Lancet 2001, 358:1115-1116.
• [6]Sheth RD, Perez MD, Goldstein SL: Cardiovascular calcifications in pediatric patients receiving maintenance dialysis. Pediatr Nephrol 2003, 18:810-813.
• [7]Filler G: Challenges in pediatric transplantation: the impact of chronic kidney disease and cardiovascular risk factors on long-term outcomes and recommended management strategies. Pediatr Transplant 2011, 15:25-31.
• [8]Cianciolo G, La Manna G, Donati G, Persici E, Dormi A, Cappuccilli ML, Corsini S, Fattori R, Russo V, Nastasi V, Coli L, Wratten M, Stefoni S: Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index? Blood Purif 2010, 29:13-22.
• [9]Kojima F, Uchida K, Ogawa T, Tanaka Y, Nitta K: Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis. Int Urol Nephrol 2008, 40:1067-1074.
• [10]Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA: FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2011. in press
• [11]Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 34:1478-83.
• [12]Mirza MA, Larsson A, Lind L, Larsson TE: Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009, 205:385-390.
• [13]Bernheim J, Benchetrit S: The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrol Dial Transplant 2011, 26:2433-2438.
• [14]Filler G, Liu D, Huang SH, Casier S, Chau LA, Madrenas J: Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease. Clin Biochem 2011, 44:435-437.
• [15]Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005, 16:2205-2215.
• [16]de Borst MH, Vervloet MG, Ter Wee PM, Navis G: Cross Talk Between the Renin-Angiotensin-Aldosterone System and Vitamin D-FGF-23-klotho in Chronic Kidney Disease. J Am Soc Nephrol 2011, 22:1603-1609.
• [17]Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, Carlier MC, Richard M, Cochat P: The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 2010, 95:1741-1748.
• [18]Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED: Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 2011, 26:945-951.
• [19]Ix JH, Shlipak MG, Wassel CL, Whooley MA: Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 2010, 25:993-997.
• [20]Filler G, Lepage N: Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol 2003, 18:981-985.
• [21]Filler G, Huang SH, Sharma AP: Should we consider MMF therapy after rituximab for nephrotic syndrome? Pediatr Nephrol 2011, 26:1759-62.
• [22]Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S: Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002, 87:4957-4960.
• [23]Wong H, Mylrea K, Feber J, Drukker A, Filler G: Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int 2006, 70:585-590.
• [24]Magnusson P, Hansson S, Swolin-Eide D: A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. Scand J Clin Lab Invest 2010, 70:15-20.
• [25]Siomou E, Challa A, Printza N, Giapros V, Petropoulou F, Mitsioni A, Papachristou F, Stefanidis CJ: Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr Nephrol 2011, 26:1105-1114.
• [26]Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Juppner H, Salusky IB: Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009, 94:511-517.
• [27]Wesseling-Perry K, Tsai EW, Ettenger RB, Juppner H, Salusky IB: Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dialysis Transplant 2011, 26:3779-84.
• [28]Filler G, Liu D, Sharma AP, Grimmer J: Are fibroblast growth factor 23 concentrations in renal transplant patients different from non-transplanted chronic kidney disease patients? Pediatr Transplant 2012, 16:73-77.
• [29]Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003, 64:2272-2279.